Free tool
FAERS Monitor: Akynzeo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210493 or its brand name (Akynzeo, Fosnetupitant Chloride Hydrochloride, Palonosetron Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,200
Serious
1,119
93% of reports
Hospitalization
620
Death reported
170
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea129
- fatigue92
- diarrhoea91
- neutropenia89
- dyspnoea75
- vomiting72
- death68
- pyrexia57
- off label use56
- febrile neutropenia52
- anaemia46
- decreased appetite46
- asthenia45
- constipation45
- hypotension43
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 9 |
| 2016 | 18 |
| 2017 | 43 |
| 2018 | 75 |
| 2019 | 152 |
| 2020 | 148 |
| 2021 | 188 |
| 2022 | 92 |
| 2023 | 78 |
| 2024 | 113 |
| 2025 | 148 |
| 2026 | 136 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,959 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 52 | 13.7 | 10.5 | 604 |
| neutropeniaSignal | 89 | 11.5 | 9.4 | 846 |
| anaemiaSignal | 46 | 4.2 | 3.2 | 111 |
| hypotensionSignal | 43 | 3.8 | 2.8 | 85 |
| constipationSignal | 45 | 3.6 | 2.7 | 83 |
| decreased appetiteSignal | 46 | 3.5 | 2.6 | 79 |
| pyrexiaSignal | 57 | 2.9 | 2.2 | 70 |
| nauseaSignal | 129 | 2.9 | 2.4 | 160 |
| vomitingSignal | 72 | 2.7 | 2.1 | 76 |
| diarrhoeaSignal | 91 | 2.5 | 2.0 | 81 |
| dyspnoeaSignal | 75 | 2.3 | 1.9 | 57 |
| astheniaSignal | 45 | 2.1 | 1.6 | 25 |
| fatigueSignal | 92 | 2.1 | 1.7 | 52 |
| death | 68 | 1.4 | 1.1 | 7 |
| off label use | 56 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.